Momenta Pharmaceuticals, Inc. (MNTA)

[Boing x 2]

Just found this,

"The Global Intravenous Immunoglobulin (IVIg) Market is growing at the CAGR of ~5.9% during the forecast period and expected to reach US$ 8337.2 million by 2023."

M254 has a big opportunity here with an FDA approval.

There are over 80 diseases that hsIVig can treat in the future. I saw one article this am. that said there is a lot of off label usage. That tells me due to the expense of getting each drug approved a lot of doctors might not be waiting and using it for those various diseases.

Sunday starts the second half. Let's roll.

Boing X 2